澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

DIMERIX LTD

0.220

0.000

成交量：43.81万

成交额：9.83万

市值：1.32亿

市盈率：-4.43

高：0.240

开：0.240

低：0.217

收：0.220

52周最高：0.665

52周最低：0.157

股本：6.00亿

流通股本：4.68亿

量比：0.68

换手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-0.050

每股收益(LYR):-0.050

净资产收益率：-594.54%

总资产收益率：-29.36%

市净率：-8.95

市盈率(LYR):-4.43

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

DIMERIX LTD

交易所：

ASX

成立时间：

- -

员工人数：

15

公司地址：

425 Smith Street,Fitzroy,Victoria,Australia

官网：

http://dimerix.com

邮编：

3065

电话：

传真：

61 8 9388 8256

简介：

Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/DXB.AU/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.22,"timestamp":1791781920000,"preClose":0.22,"halted":0,"volume":438080,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"未开盘","change":0,"latestTime":"10-12 16:12:00 AEDT","open":0.24,"high":0.24,"low":0.217,"amount":98319,"amplitude":0.104545,"askPrice":0.235,"askSize":167875,"bidPrice":0.215,"bidSize":64541,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.22,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0.6827870578831872,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.22,"auctionPrice":0.22,"auctionVolume":3969,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781798198}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.6827870578831872,"shares":600396776,"dividePrice":0,"high":0.24,"amplitude":0.104545,"preClose":0.22,"low":0.217,"week52Low":0.157,"pbRate":"-8.95","psRate":"20.79","week52High":0.665,"institutionHeld":0,"latestPrice":0.22,"committee":-0.444608,"eps":-0.0497,"divideRate":0,"volume":438080,"delay":0,"ttmEps":-0.0497,"open":0.24,"prevYearClose":0.55,"prevWeekClose":0.22,"prevMonthClose":0.23,"prevQuarterClose":0.23,"fiveDayClose":0.235,"twentyDayClose":0.24,"sixtyDayClose":0.225,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":23928564,"employeeNum":15,"address":"425 Smith Street,Fitzroy,Victoria,Australia","zipCode":"3065","officePhone":"1300 813 321","officeFax":"61 8 9388 8256","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://dimerix.com","stockEarnings":[{"period":"1week","weight":-0.0638},{"period":"1month","weight":-0.12},{"period":"3month","weight":-0.0833},{"period":"6month","weight":-0.4634},{"period":"1year","weight":-0.6},{"period":"ytd","weight":-0.6}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":0.006},{"period":"3month","weight":0.0047},{"period":"6month","weight":0.0145},{"period":"1year","weight":0.0778},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.181818,"avgChangeRate":-0.092931},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020467},{"month":3,"riseRate":0.363636,"avgChangeRate":0.019402},{"month":4,"riseRate":0.272727,"avgChangeRate":0.014529},{"month":5,"riseRate":0.545455,"avgChangeRate":0.055282},{"month":6,"riseRate":0.818182,"avgChangeRate":0.166318},{"month":7,"riseRate":0.333333,"avgChangeRate":0.071825},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.073331},{"month":9,"riseRate":0.333333,"avgChangeRate":0.153245},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.090222},{"month":11,"riseRate":0.272727,"avgChangeRate":0.028595},{"month":12,"riseRate":0.454545,"avgChangeRate":0.04297}],"exchange":"ASX","name":"DIMERIX LTD","nameEN":"DIMERIX LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":null}}